

- TO: Pharmacy Providers, Physicians, Nurse Practitioners, Certified Nurse Midwives, Physician Assistants, Clinics, Long Term Care Providers, and Hospitals
- RE: CMAP COVID-19 Response Bulletin 52: Updated Guidance COVID-19 Vaccine Administration – Provided by Pharmacists, Pharmacy Interns and Pharmacy Technicians

Effective for dates of service as specified below, until the Department of Social (DSS) has notified providers in writing that the State has deemed COVID-19 to no longer be a public health emergency (PHE), DSS is:

- updating the COVID-19 vaccine administration reimbursement to \$40.00, and
- updating the guidance for vaccine administration for individuals covered under the Limited Benefit programs.

This provider bulletin provides additional and updated guidance related to the administration of COVID-19 vaccines and must be used in combination with PB 2021-06 "CMAP COVID-19 Response Bulletin 49: COVID-19 Vaccine Administration-Provided by Pharmacists, Pharmacy Interns and Pharmacy Technicians".

<u>Updated Reimbursement for One-Dose and</u> <u>Two-Dose Food and Drug Administration</u> (FDA)-Approved COVID-19 Vaccines

Consistent with guidance published by Medicare, effective retroactively for dates of service on and after March 15, 2021 and through the end of the federal PHE, DSS is increasing the rate reimbursed for administration of a COVID-19 vaccine to remain at 100% of Medicare, specifically to the Medicare national average of \$40.00 for the administration of a vaccine that is authorized by the U.S. FDA as a single dose vaccine and \$40.00 for each administration of a vaccine that has been authorized as a two (2) dose vaccine. As a result, the Connecticut Medical Assistance Program (CMAP) will reimburse an administration fee of \$40.00 for the single-dose and for both doses of two-dose vaccine.

The vaccine is currently being provided at no charge by the federal government; therefore, CMAP will not make any payment for the vaccine itself. The provider will submit a claim with an ingredient cost of \$0.01. There will be no additional dispensing fee.

For a two-dose vaccine, the pharmacy will need to submit an NCPDP Submission Clarification Code (420-DK) on the claim to distinguish between the first and second doses.

The following Submission Clarification Code values should be used to clarify the administration of a first or second dose:

• Submission Clarification Code of 2 "Other Override" to indicate the first dose is being administered

page 2

• Submission Clarification Code of 6 "Starter Dose" to indicate the second dose is being administered.

For a single-dose vaccine, the pharmacy will need to submit an NCPDP Submission Clarification Code (420-DK) on the claim.

• Submission Clarification Code of 6 "Starter Dose" on the single dose vaccine claim.

*At the conclusion of the designated federal PHE period, DSS will reassess the reimbursement set for administration of a COVID-19 vaccine and update it according to current reimbursement methodologies for each applicable provider category. Providers will be notified in writing prior to any reimbursement change.

<u>Updated Guidance - Vaccine</u> <u>Administration for Individuals Covered</u> <u>under the Limited Benefit Groups and Non-</u> <u>citizens</u>

Consistent with section 9811 of the federal American Rescue Plan Act of 2021, Public Law 117-2, effective for dates of services retroactive to March 11, 2021 and ending on the last day of the first calendar quarter that begins one year after the last day of the federal PHE period, CMAP will reimburse for the administration of the COVID-19 vaccine for members covered under the **Tuberculosis Limited Benefit, Family** Planning Limited Benefit, and the COVID-**19 Testing Group.** Providers should refer to PB 2021-06 and this PB for guidance related to providers eligible to bill for administration of the COVID-19 vaccine, reimbursement, and claims submission requirements.

As previously communicated in PB 2021-06, COVID-19 vaccine administration to **noncitizens (***who do not qualify for Medicaid or CHIP coverage due to their** **immigration status)** continues to be not reimbursable under CMAP. Providers should continue to seek reimbursement through the U.S. Health Resources and Services Administration (HRSA) to the extent available. For more information, see this link to the HRSA Web site:

https://www.hrsa.gov/coviduninsuredclaim

<u>Posting Instructions</u>: Policy transmittals can be downloaded from the Web site at <u>www.ctdssmap.com</u>.

Distribution: This policy transmittal is being distributed to providers of the CMAP by Gainwell Technologies.

<u>Responsible Unit:</u>

DSS, Division of Health Services, Integrated Care, Herman Kranc, Pharmacy Manager at 860-424-5218 or <u>herman.kranc@ct.gov</u>

Date Issued: March 2021